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E-mail address: ixp004@shsu.edu (I. Petrikovics).Present studies focused on the in vitro testing, the solubility enhancement and the in vivo testing of
methyl propyl trisulﬁde (MPTS), a newly identiﬁed sulfur donor to treat cyanide (CN) intoxication. To
enhance the solubility of the lipophilic MPTS, various FDA approved co-solvents, surfactants and their
combinations were applied. The order of MPTS solubility in the given co-solvents was found to be the fol-
lowing: ethanol >> PEG 200  PEG400  PEG300 > PG. The maximum solubility of MPTS was found at
90% ethanol of 177.11 ± 12.17 mg/ml. The order of MPTS solubility in different surfactants is Cremophor
EL > Cremophor RH40 > polysorbate 80 > sodium deoxycholate > sodium cholate. The maximum solubil-
ity of 40.99 mg/ml was achieved with 20% Cremophor EL. A synergistic solubilizing effect encountered
with the combination of 20% Cremophor EL + 75% ethanol lead to a 2900-fold increase (compared to
water solubility) in solubility. The in vivo efﬁcacy using intramuscular administration was determined
on a therapeutic mice model and expressed as a ratio of CN LD50 with and without the test antidote(s)
(APR). Intramuscular administration was shown to be effective and the therapeutic antidotal protection
by MPTS alone and MPTS + thiosulfate (TS) was signiﬁcantly higher than the present therapy of TS.
 2013 Elsevier B.V. All rights reserved.1. Introduction
The major mechanism which removes cyanide (CN) from the
body is its biotransformation to the less toxic thiocyanate (SCN)
in the presence of a sulfur donor (SD) and a sulfurtransferase en-
zyme such as rhodanese (Rh) (Way, 1983). The SD component of
the present therapy of Nithiodote™, the inorganic sodium thiosul-
fate (TS), has limitations due to its high Rh dependency, relative
low SCN formation efﬁcacy, and low cell penetration ability to
reach the endogenous Rh localization. The antidotal approach of
co-administering TS with puriﬁed Rh encapsulated within various
enzyme carriers such as erythrocytes (Way et al., 1985), and poly-
meric nano-delivery systems (Petrikovics et al., 2010) made the SD
and Rh available in the blood stream to react immediately with the
absorbed CN before it reaches its target points in the body. This
way, the two components of the CN antidotal systems: (a) an
appropriate SD and (b) Rh enzyme, protected from adverse
immunologic reactions by macrophages, are readily available inll rights reserved.
, cyanide; SCN, thiocyanate;
EG, polyethylene glycol; PG,
R, relative antidotal potency
: +1 936 294 4996.the circulation. This approach proved to be signiﬁcantly efﬁcient:
a prophylactic antidotal protection of over 9 LD50 was achieved
when sodium nitrite (SN) was co-administered with TS and encap-
sulated external Rh (Way et al., 1991). However, still there were
some limitations with the encapsulated Rh and TS due to the prod-
uct inhibition by the formed sulﬁte. This approach was further im-
proved by the application of organic thiosulfonates with superior
SCN formation efﬁcacy and superior cell penetration capability to
that of the inorganic TS (Petrikovics et al., 1994). When butane
thiosulfate was administered with encapsulated Rh in combination
with SN, a prophylactic antidotal protection of 14 LD50 was
achieved (Petrikovics et al., 1995). Sulfur donors with higher lipo-
philicity can penetrate cell membranes and reach the mitochon-
drial Rh, and are expected to be efﬁcient even without external
Rh administration. Various synthetic and naturally occurring org-
ano-sulfur molecules were tested in vitro and in vivo and compared
to the inorganic TS (Baskin et al., 1999; Frankenberg, 1980; Iciek,
2001). Several garlic originated organo-sulfur molecules were eval-
uated as SDs and CN acceptors (Ashani et al., 2006; Block, 1985;
Iciek et al., 2005).
Although great progress was achieved in the ﬁeld, especially in
the prophylactic treatment of cyanide intoxication, there are still
numerous factors that could be improved, including the need to
identify further, possibly more effective organo-sulfur molecules
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ment. Latter is important since the presently used antidotes are all
intravenous preparations, which in the case of a mass casualty sce-
nario are difﬁcult to administer in time due to the large number of
people involved. An intramuscular preparation would be easier
and quicker to administer or even self-administer which in turn
would be more favorable in such a situation.
One of the main drawbacks of the organo-sulfur donors is their
very low water solubility, which hinders their application in liquid
dosage forms. To overcome this issue, an appropriate solubility
enhancing method or solvent system has to be developed that is
capable of dissolving the compounds at therapeutically relevant
concentrations. In the case of parenterals this poses extra difﬁcul-
ties as the available excipients for solubilizing lipophilic molecules
is limited and their applicable concentration range is also re-
stricted (Liu, 2008; Strickley, 2004).
Present study focused on the in vitro efﬁcacy characterization of
methyl propyl trisulﬁde (MPTS), an SDmolecule that to our present
knowledge has never been used in combating cyanide intoxication,
and on its in vivo antidotal efﬁcacy determined on a therapeutic
mice model. Furthermore, since the identiﬁed SD is a highly lipo-
philic molecule it was the aim of the study to design a solvent sys-
tem that is capable of dissolving the drug candidate in
therapeutically effective doses. In developing the system another
aim of the study was realized, namely to identify a vehicle/vehicle
mixture that could serve the animal studies in which the intramus-
cular administration was tested and later be the base of an appro-
priate kit for a mass casualty scenario. This was achieved by
enhancing the solubility of the lipophilic MPTS with the applica-
tion of FDA approved co-solvents, surfactants and their combina-
tions. The aim of the animal studies was therefore dual as the
test not only gave answer to the in vivo efﬁcacy of the drug candi-
date but would also answer the question of whether the drug
shows a fast enough absorption from an intramuscular injection
for combating cyanide intoxication.Table 1
Gas chromatograph parameters.
Injection source GC auto-loading sampler (ALS)
Injection volume 1.0 ll
Injection port temperature 250 C
Injection mode Split
Split ratio 60:1
Carrier gas Helium
Carrier gas velocity 1.0 ml/min
Carrier gas pressure 7.6522 psi
Initial temperature of column 50 C
Initial temperature duration 2 min
Temperature ramp 5 C/min
Final temperature of column 250 C
Final temperature duration 5 min2. Materials and methods
2.1. Materials
Materials for the conversion test were potassium cyanide (KCN),
formaldehyde, ferric nitrate reagent, monobasic sodium phosphate
monohydrate and dibasic sodium phosphate anhydrous (VWR
International, Suwanee, GA, USA). Methyl propyl trisulﬁde (50%
purity; water solubility = 0.15 ± 0.003 mg/ml) was purchased from
Sigma–Aldrich (St. Louis, Missouri, USA), TS were purchased from
VWR International (Suwanee, GA, USA). Ethanol, PEG 200, PEG
300, PEG 400, PG (VWR International, Suwanee, GA, USA), Cremo-
phor EL, Cremophor RH40, sodium cholate, sodium deoxycholate,
polysorbate 80 (Sigma Aldrich, St. Louis, MO, USA) were used as sol-
ubilizers. Cyclohexanone (Sigma–Aldrich, St. Louis, MO, USA) was
used as solvent for the GC–MS measurements. KCN solutions
(1.0 mg/ml and 3.5 mg/ml) were used throughout the animal stud-
ies. 250, 100 and 50 ll Hamilton Luer-lock syringes (VWR Interna-
tional, Suwanee, GA, USA) were used in the animal studies with 27G
1/2 needles for intramuscular and 25G 1½ needles (VWR Interna-
tional, Suwanee, GA, USA) for subcutaneous injection.Table 2
Mass spectrometer parameters.
EMV mode Relative (+200)
EM voltage 1118
Solvent delay 2.00 min
Source temperature 230 C
Quadrupole temperature 150 C
Electron energy 70 eV2.2. In vitro efﬁcacy test
In vitro efﬁcacy of MPTS was determined based on its ability to
convert CN to SCN. The method applied was a spectrophotometric
measurement of the formed SCN based on the method of Westley
(1981) with minor modiﬁcations (Petrikovics et al., 1995). Brieﬂy,
200 ll of various concentrations of SDs, 200 ll of 10 mM phos-phate buffered saline, 200 ll of 250 mM KCN and 400 ll of deion-
ized water were mixed. The reaction was incubated for 5 min and
was quenched with 500 ll of 15% (v/v) formaldehyde. 1.5 ml of fer-
ric nitrate reagent was added to form a reddish brown complex
(Fe(SCN)3) that was quantitatively determined at 464 nm using a
spectrophotometer (Thermo Fisher Scientiﬁc, Waltham, MA,
USA). Tests were performed with MPTS and TS at concentrations
ranging from 25 mM to 0.156 mM with two fold serial dilutions
in between.
2.3. Solubility studies
The solubility of MPTS was determined in co-solvents, surfac-
tants and their combinations. Aqueous solutions of co-solvents
and surfactants were prepared at 10%, 25%, 50%, 75%, 90% and
1%, 5%, 10%, 15%, 20% respectively. Based on the solubility enhanc-
ing efﬁcacy of the co-solvent/water and surfactant/water systems
the most effective excipients were combined into one system
forming a co-solvent/surfactant/water system. Thus combinations
of Cremophor EL, ethanol and PEG200 were prepared, where the
concentration of the surfactant was 5%, 10%, 15%, 20% and the con-
centration of the co-solvents was 50%, 62.5% and 75%.
Triplicates of the solvent systems were prepared in glass vials,
excess MPTS was added to the solutions and the vials were sealed
to eliminate the possibility of evaporation. The samples were then
vortexed (Heidolph Multi Reax, Heidolph Instruments, and Cin-
naminson, NJ, USA) for 20 min and left to equilibrate at room tem-
perature. After equilibration (determined as 1 week) an aliquot of
the samples was centrifuged (Galaxy 20R, VWR International,
Suwanee, GA, USA) at 5000 rpm for 5 min to ensure sedimentation
of the excess MPTS and the drug content of the saturated solution
was measured using a GC–MS method detailed in Section 2.4. Prior
to GC–MS measurements the internal standard (1 mg/ml of dibu-
thyl disulﬁde; DBDS) was added to the samples and dilution with
ethanol and cylcohexanone was performed.
2.4. GC–MS measurement
A GC–MS method was chosen for the quantitative determina-
tion of MPTS. The system consisting of an Agilent Technologies
7890A GC with a 7683 autosampler and a 5975C VL MSD,
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DB-5MS column (30 m  0.25 mm ID, 0.25 lm ﬁlm thickness; Agi-
lent Technologies, Santa Clara, CA, USA) was used with He carrier
gas at a ﬂow rate of 1 ml/min and pressure of 7.6522 psi. The con-
ditions for GC and MS are detailed in Tables 1 and 2.Fig. 1. CN to SCN conversion rate of MPTS and TS.2.5. Dielectric constant measurements
Dielectric constant measurements were performed using a
HP4285A LCR meter. The AC signal amplitude for the impedance
measurement was 100 mV, and the applied frequency ranged from
75 kHz to 30,000 kHz in logarithmic distribution. All measure-
ments were carried out at 20 ± 1 C in a thermostatable cylindrical
cell (originally prepared for a Radelkis OH-301 type dielectrome-
ter) using an interface. Cyclohexane and ethanol were used as ref-
erence for determining the capacitances of the applied empty cell.
The dielectric constant results are presented as values measured at
3022.2 kHz.2.6. Animal studies
LD50 studies were conducted using the Dixon up-and-down
method with 1.0 mg/ml and 3.5 mg/ml KCN solutions, a 50 mg/
ml MPTS stock solution, and a 100 mg/ml TS solution. Male CD-1
mice (Charles River Breeding Laboratories, Inc., Wilmington, MA)
weighing 18–28 g were housed at 21 C and in light-controlled
rooms (12-h light/dark, full-spectrum lighting cycle with no twi-
light), and were furnished with water and 4% Rodent Chow (Teklad
HSD, Inc., CITY, WI) ad libitum. All animal procedures were con-
ducted in accordance with the guidelines by ‘‘The Guide for the
Care and Use of Laboratory Animals’’ (National Academic Press,
2010), accredited by AAALAC (American Association for the Assess-
ment and Accreditation of Laboratory Animal Care, International).
At the termination of the experiments, surviving animals were
euthanized in accordance with the 1986 report of the AVMA Panel
of Euthansia.
Animal studies were conducted as therapeutic experiments
using the up-and-down method for LD50 determination and the
estimated 95% conﬁdence interval was also calculated (Dixon,
1965). Based on the weight of the animal an initial dose of KCN
was injected subcutaneously from the KCN stock solution. Within
30 s, based on the weight of the animal, a predetermined dose
(either 100 mg/kg or 200 mg/kg) of MPTS (50 mg/ml in 10% Crem-
ophor EL + 50% ethanol) or TS (100 mg/ml in water) was injected
intramuscularly into the rear right leg of the mouse. In case of
the combination studies MPTS was injected intramuscularly into
the right leg, TS intramuscularly into the left leg both within 30 s
of the KCN administration. The mice were then inspected and
determined to be alive or dead. Based on the observation, a higher
or a lower dose of KCN was injected in the following stage. This
was repeated until enough data was collected to determine the
LD50 values, and the computer declared that the stopping condi-
tion has been met. For each LD50 determination, 9–14 animals
were used.3. Results and discussion
3.1. In vitro efﬁcacy test
In the ﬁrst set of experiments the in vitro efﬁcacy of MPTS was
tested in order to determine its efﬁciency in converting CN to SCN.
This effect was then compared to that of TS, which is used as the SD
component in one of the currently approved CN antidote kits. Com-
parison of its activity with that of MPTS would thus give a valuableinsight on the in vitro efﬁcacy of MPTS. Fig. 1 shows the CN to SCN
conversion rate of MPTS and TS.
Results show that the conversion rate produced by MPTS is
higher than that of TS at all tested concentrations, indicating the
usefulness of the newly tested molecule in combating CN intoxica-
tion. A 2-fold increase in conversion rate was already seen at
concentrations as low as 0.156 mM and as the concentration of
the two SDs increased the relative efﬁcacy of MPTS compared to
TS increased to a substantial 44-fold at 25 mM SD concentration.
It was also seen that the reaction rates are directly proportional
to the concentrations of MPTS and TS (equation MPTS:
y = 0.0058x + 0.0024; R2 = 0.9992; equation TS: y = 0.00008x +
0.0011; R2 = 0.9986) indicating that the efﬁcacy of MPTS in future
in vivo studies might prove to be dose dependent. Based on these
in vitro ﬁndings it can be concluded that MPTS is an effective sulfur
donor and therefore solubilization of the drug for intramuscular
in vivo studies was initiated.
3.2. Solubility of MPTS in co-solvents
Solubilization studies were divided into three steps: in the ﬁrst
and second steps the solubility of MPTS was determined in co-sol-
vent/water and surfactant/water systems. In the ﬁnal phase of the
studies, based on the results of the ﬁrst two stages, the most effec-
tive surfactant and co-solvents were combined into one system
and the solubility of the antidote candidate molecule was deter-
mined in such systems in the hope of further increasing its
solubility.
The effect of co-solvent/water systems on the solubility of MPTS
was examined using ethanol, PEG 200, PEG 300, PEG 400 and pro-
pylene glycol at concentrations of 10%, 25%, 50%, 75% and 90%.
Fig. 2 shows the solubility of MPTS in the co-solvents. The inserted
ﬁgure shows the solubilized drug concentrations up to a higher va-
lue, while the large ﬁgure shows the values up to a lower concen-
tration so as to facilitate the distinction between the solubilizing
effects of the PEGs.
The solubility enhancing effect attributed to the co-solvents can
be explained (a) by their ability to interrupt the hydrogen bonding
structure of the watermolecules, thus decreasing the squeezing out
effect of non-polar molecules from the polar solvent; and (b) by
their ability to decrease the dielectric constant of the solvent sys-
tem. The exponential solubility curve seen in the case of MPTS
(Fig. 2) correlateswell with the previously published solubility tests
using co-solvents (Higuchi et al., 1953). These studies, known as the
log-linear model, reported that a linear increase in the concentra-
tion of the co-solvent increases the solubility of drugs exponen-
tially, (Yalkowsky et al., 1972, 1976). Results show that the most
Fig. 2. Solubility of MPTS in various co-solvents at increasing concentrations.
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MPTS at 90% and 44.35 ± 5.15 mg/ml MPTS at 75%. PEG200,
PEG300 and PEG400 exerted similar solubility enhancing capaci-
ties, but their solubilizing power falls short of the one encountered
with ethanol. Based on the solubility enhancing effect of the co-sol-
vents, ethanol and PEG200 were picked to be included in further
studies when co-solvents were combined with surfactants.3.3. Solubility of MPTS in surfactants
In step two of the studies, the effect of surfactant/water systems
on the solubility of MPTS was examined using Cremophor EL,
Cremophor RH40, polysorbate 80, sodium cholate and sodium
deoxycholate at 1%, 5%, 10%, 15% and 20%. Fig. 3 shows the solubil-
ity of MPTS in the various surfactant compositions.
The solubilizing effect of surfactants rests on their ability to ori-
ent to the interface between a molecule and water and their ability
to form micelles above the critical micellar concentration in aque-
ous solutions (McBain, 1913). All surfactants used in this experi-
ment were above this concentration (cmc values: Cremophor
EL = 0.002%, Cremophor RH40 = 0.039%, polysorbate 80 = 0.016%,
sodium cholate = 0.388–0.603%, sodium deoxycholate = 0.083–
0.249%), thus the solubilizing effect can be associated with the
number and size of micelles formed (Coello et al., 1996; McBain,
1913; Rowe et al., 2009; Tellingen van et al., 1999; Wan and Lee,
2006). Fig. 3 shows that the solubility of MPTS increased linearly
with the linear increase in the concentration of the surfactants.
Out of the tested surfactants, the highest solubility of MPTS was
achieved in Cremophor EL at all tested concentrations, with maxi-
mum MPTS solubility of 40.99 ± 1.55 mg/ml at 20% Cremophor EL
concentration. All the other surfactants increased the solubility ofFig. 3. Solubility of MPTS in various surfactants at increasing concentrations.the molecule at different rates, in the following order: Cremophor
EL > Cremophor RH40 > polysorbate 80 > sodium deoxycho-
late > sodium cholate. Generally, results show that with the use
of non-ionic surfactants a superior solubility enhancing effect can
be achieved compared to the ionic surfactants (sodium cholate
and deoxycholate). Based on the solubility of MPTS Cremophor
EL was chosen for further studies.3.4. Solubility of MPTS in co-solvent surfactant combinations
It is well known that the amount of excipients present in a com-
position, especially in an intramuscular parenteral preparation,
might have a signiﬁcant effect on the overall toxicity of the ﬁnal
preparation (Amin and Dannenfelser, 2006; Medlicott et al.,
1998). Therefore, it was the aim of the study to develop a compo-
sition with an adequate solubilizing power while utilizing as little
amount of excipients as possible. The use of ethanol was not ex-
cluded based on the fact that the administration of a highly con-
centrated solution of MPTS would mean that the total volume of
injection is low, therefore the administered dose of ethanol is also
very low. Taking the above, and the solubility enhancing effect of
co-solvents and surfactants into consideration, it was evident that
a more effective systemwas needed to solubilize higher concentra-
tions of the drug. Although the combination of co-solvents with
surfactants were shown earlier to have only few advantages, in
some cases their combination is desirable, as shown by the mar-
keted compositions of cyclosporine and paclitaxel which were sol-
ubilized in Cremophor + ethanol combinations (Kawakami et al.,
2004, 2006; Kovacs et al., 2009, 2010). Therefore, the excipientsFig. 4. Solubility of MPTS in the combinations of Cremophor EL with ethanol,
PEG200 and ethanol:PEG200 = 1:1 (co-solvents at 75%).
Table 3
Solubility of MPTS in various systems comprising 75% co-solvent, surfactant and their combination.
Cremophor EL conc. (%) Co-solvent
MPTS solubility (mg/ml)
No co-solvent 75% Ethanol 75% Ethanol:PEG200 = 1:1 75% PEG200
Measured Calculated Measured Calculated Measured Calculated Measured
0 – – 44.3 – 18.9 – 12.35
5 8.46 52.76 86.70 27.36 45.35 20.81 9.72
10 23.67 67.97 117.89 42.57 69.03 36.02 13.65
15 33.35 77.65 230.47 52.25 76.93 45.70 24.16
20 40.98 85.28 434.79 59.88 92.38 53.33 31.71
Remarks – Synergistic solubilizing effect Synergistic solubilizing effect Negative solubilizing effect
Fig. 5. Solubility of MPTS in Cremophor EL + ethanol combinations.
Table 5
Dielectric constant values of tested solvent systems.
Sample Average of dielectric constant SD
50% Ethanol 53.05 0.0108
60% Ethanol 47.13 0.0163
65% Ethanol 44.50 0.0031
70% Ethanol 41.83 0.0016
75% Ethanol 38.92 0.0039
5% Cremophor EL + 50% ethanol 56.42 0.1463
10% Cremophor EL + 50% ethanol 50.44 0.0118
15% Cremophor EL + 50% ethanol 48.66 0.0120
20% Cremophor EL + 50% ethanol 45.60 0.0063
356 K. Kovacs et al. / European Journal of Pharmaceutical Sciences 49 (2013) 352–358that showed the highest solubilizing power during the ﬁrst two
phases of the studies were combined in the hope of developing a
solvent system that is capable of solubilizing higher MPTS concen-
trations than those seen in co-solvent/water and surfactant/water
systems. Cremophor EL was chosen as the surfactant (it solubilized
the most MPTS out of the surfactant type excipients), and ethanol
and/or PEG200 were chosen as the co-solvents.
The above mentioned co-solvents were combined with
increasing amounts of Cremophor EL to form the following solvent
systems: surfactant + 75% ethanol, surfactant + 75% PEG 200,
surfactant + 37.5% ethanol + 37.5% PEG 200 (=75% ethanol:
PEG200 = 1:1). Fig. 4 shows the solubility of MPTS in these solvents.
The solubilizing effect of the tested systems can be classiﬁed as
negative, additive or synergistic based on how much more or less
MPTS is solubilized in the surfactant/co-solvent/water combina-
tion than in the corresponding co-solvent/water and surfactant/
water systems. The measured solubility of MPTS in the combina-
tion system of Cremophor EL and PEG200 was lower than the cal-
culated solubility of the antidote candidate if the solubility values
measured in Cremophor EL/water and PEG200/water were added
(Table 3). In the case of the combination of Cremophor EL with eth-
anol and Cremophor EL with ethanol and PEG200 at a ratio of 1:1 aTable 4
Solubility of MPTS in various systems comprising 75%, 62.5% and 50% ethanol, surfactant
Cremophor EL conc. (%) Co-solvent
MPTS solubility (mg/ml)
No co-solvent 75% Ethanol
Measured Calculated Measured
0 – – 44.3
5 8.46 52.76 86.70
10 23.67 67.97 117.89
15 33.35 77.65 230.47
20 40.98 85.28 434.79
Remarks – Synergistic solubilizing effectsynergistic solubilizing effect was encountered in both systems,
meaning that measuring the solubility of MPTS in the excipients
separately and adding the results would lead to a lower concentra-
tion of SD than the one seen when the excipients were mixed in
one system and the solubility of MPTS was determined in that sol-
vent (Table 3). The level of synergism encountered with the two
systems differed, Cremophor EL + ethanol exhibiting a larger rate.
Based on the solubilizing power of the solvent systems compris-
ing Cremophor EL in combination with ethanol or PEG200 or eth-
anol and PEG200 it was concluded that the combination of
Cremophor EL and ethanol was the most effective solvent system
for solubilizing MPTS. Furthermore, this system showed a marked
synergistic solubilizing effect at 75% ethanol content. It was the
aim of the research to develop a solvent system that comprises
excipients in concentrations as low as possible while still exerting
substantial solubilizing power, therefore, the synergistic solubiliz-
ing effect of Cremophor EL and ethanol were further studied. The
solubility of MPTS was determined in Cremophor EL and ethanol
combinations where the concentration of the co-solvent was de-
creased to 62.5% and 50%. Solubility of MPTS in such systems is
presented together with the solubility values of Cremophor
EL + 75% ethanol (for the ease of comparison) in Fig. 5.
Results proved that the synergistic solubilizing effect encoun-
tered at 75% was also detected at 62.5% and 50% ethanol contentand their combination.
62.5% Ethanol 50% Ethanol
Calculated Measured Calculated Measured
– 16.3 – 4.8
24.76 42.37 13.26 32.75
39.97 66.51 28.47 60.14
49.65 83.01 38.15 78.71
57.28 116.32 45.78 112.69
Synergistic solubilizing effect Synergistic solubilizing effect
Table 6
APR and RAPR values of the antidotes.
Exp. # Treatments APR RAPR (dose effect) RAPR (MPTS vs. TS)
1 MPTS 100 mg/kg (intramuscular) 1.2
2 MPTS 200 mg/kg (intramuscular) 1.67 1.67/1.2 = 1.39 1.67/1.25 = 1.33
3 TS 100 mg/kg (intramuscular) 1.1
4 TS 200 mg/kg (intramuscular) 1.25 1.25/1.1 = 1.13
5 MPTS 200 mg/kg (intramuscular) +
TS 200 mg/kg (intramuscular)
3.66 – 3.66/1.67 = 2.19
3.66/1.25 = 2.92
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fect of the co-solvent/surfactant/water systems is the following:
Surfactants form micelles above their critical micelle concentra-
tion, but the addition co-solvents, such as ethanol, increase the
cmc. Furthermore, above a certain concentration (25% for polyoxy-
ethylene (23) lauryl alcohol, a non-ionic surfactant) co-solvents in-
hibit micelle formation of the surfactants (Becher, 1965). The
concentration of ethanol in the tested solvents is well above the
referenced concentration, thus surfactants do not form micelles
in the applied solubility enhancing systems. Therefore, the solubi-
lizing effect of the surfactant/co-solvent/water mixture does not
depend on the number of micelles. To rule out the solubilizing ef-
fect based solely on the change in the polarity of the solvents their
dielectric constant was tested. It was seen that the addition of
Cremophor EL increased the dielectric constant of the solvents
compared to that of water/ethanol systems (Table 5). Since a de-
crease in dielectric constant increased the solubility of MPTS in
water/ethanol systems it was concluded that an increase in the
dielectric constant should have decreased its solubility. The oppo-
site phenomenon was encountered thus it was concluded that the
solubilizing effect of the solvent systems is probably due to the for-
mation of a mixture with a determined ratio of surfactants, ethanol
and active ingredient and not due to the change in the polarity of
the solution.
As it was the aim of the experiments to reduce the concentra-
tion of the excipients as much as possible but still be able to solu-
bilize 50 mg/ml of MPTS, the ﬁnal composition that was chosen for
animal studies comprised 10% Cremophor EL and 50% ethanol.3.5. Animal studies
As a result of the solubility studies, compositions that were able
to solubilize signiﬁcant amounts of MPTS were developed. A com-
position comprising 10% Cremophor EL, 50% ethanol and 50 mg/ml
MPTS was chosen for the animal studies. The in vivo efﬁcacy stud-
ies were performed with MPTS alone (dose = 100 mg/kg and
200 mg/kg) and TS alone (dose = 100 mg/kg and 200 mg/kg) and
their combination with the doses of 200 mg/kg for each. Therapeu-
tic antidotal potency ratios (APRs) of the drugs and their combina-
tions are shown in Table 6. The following were used for the
calculation of the antidote potency ratio (APR) and the relative
antidote potency ratio (RAPR): APR = LD50 of CN with the anti-
dote(s)/LD50 of CN without antidote(s) (control); relative antidotal
potency ratio (RAPR) = APR(1)/APR(2).
The antidotal efﬁcacy tests demonstrated the superior effect of
MPTS over TS (Exp. 1 vs. Exp. 3; and Exp. 2 vs. Exp. 4). The positive
dose effects are also demonstrated: MPTS alone provided a 1.2
LD50 protection when the dose was 100 mg/kg, while the double
dose (200 mg/kg) provided an enhanced protection with the APR
of 1.67 (RAPR = 1.39). TS alone provided only a slight protection
with the APR of 1.1 when the dose was 100 mg/kg, and when the
dose was doubled (200 mg/kg), the APR was enhanced to 1.25
(RAPR = 1.13). Employing the same dose of 200 mg/kg for both
components of the combination with MPTS and TS (Exp. 5), theantidotal protection was signiﬁcantly enhanced to 3.66 LD50.
The enhancement by TS was 2.19 compared to MPTS alone. The
enhancement by MPTS was 2.92 compared to TS alone. The tests
not only showed that MPTS is effective in combating cyanide intox-
ication but it also revealed that the newly identiﬁed molecule is
more effective than the currently used TS. Furthermore, it was also
shown that intramuscular administration is an effective way of
applying the antidote as absorption of the molecule from the mus-
cle was fast enough to counteract the toxic effects of cyanide.4. Conclusion
The identiﬁcation of a possible antidote (MPTS) for CN intoxica-
tion and its solubilization for the therapeutic antidotal studies
using a lethal animal model were addressed in this study. Based
on in vitro CN to SCN conversion testing of potential sulfur donors
it was concluded that MPTS is a potentially effective molecule be-
cause its in vitro efﬁcacy was superior to that of TS, the SD compo-
nent in one of the currently approved antidote kits. Following the
identiﬁcation of the SD it was seen that it is a highly lipophilic mol-
ecule with low water solubility, thus its solubilization was initi-
ated. Solubility studies revealed that FDA approved excipients,
such as co-solvents and surfactants, were able to dissolve MPTS,
but a complex system was needed to further increase solubilizing
capacity and develop a solvent that can dissolve MPTS at therapeu-
tically relevant concentrations. Further studies showed that co-sol-
vent-surfactant combinations were effective solubilizers and that
combinations comprising Cremophor EL and ethanol exerted the
largest solubilizing power. Based on these studies and taking into
consideration the possible toxicity of the excipients, the ﬁnal prep-
aration of 10% Cremophor EL + 50% ethanol was chosen for in vivo
efﬁcacy tests. Therapeutic antidotal potency ratios measured with
the identiﬁed SD candidate, evaluated in a lethal animal model,
established the efﬁcacy of MPTS alone and in combination with
TS. A very promising APR value of 3.6 was achieved with the com-
bination of MPTS and TS. Furthermore, the performed studies also
proved that intramuscular administration is an effective way of
applying the antidote as the absorption of the molecule from the
muscle was fast enough to counteract the toxic effects of cyanide.
Based on the results, MPTS was proven to be a promising effective
molecule in the ﬁght against CN poisoning, and the proposed sol-
vent system and administration route may serve as the base for
an intramuscular parenteral dosage form of MPTS.Acknowledgements
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